The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients
Open accessAbstract
PURPOSE: Real-life clinical outcomes of patients treated with anti-VEGF drugs for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or macular edema secondary to branch retinal vein occlusion (BRVO) are often inferior to results from randomized clinical trials. This observational cohort study investigates treatment adherence and real-life clinical outcomes within the first year of treatment. PATIENTS AND METHODS: A total of 708 treatment-naïve patients (466 nAMD, 134 DME, and 108 BRVO) were included. Patients were followed with a PRN treatment protocol with three intravitreal injections (IVIs) and a series of 3 monthly injections in case of persistent or recurrent disease activity, as determined by monthly follow-up exams including optical coherence tomographies. Occurrence of gaps of >56 days between treatments or follow-up (nonadherence [NA]) and the reasons for NA (patient- or center-associated) as well as disease activity within the first 12 months of treatment were analyzed. Visual acuity (VA) as well as numbers and dates of optical coherence tomography and IVI were extracted from medical records. RESULTS: >0.05). CONCLUSION: NA to treatment and follow-up regimens is a common problem in the management of patients with AMD and DME and limits clinical treatment outcomes under real-life conditions. Patients with DME have the highest risk of patient-associated NA, associated with a higher risk for significant VA loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822 · cited 1×
“In AMD, Phase III trials found a significant gain in best-corrected visual acuity (BCVA) after treatment that could be maintained over a course of 24 months.(1,2,11) Real-life studies, however, found only a stabilization of BCVA and the initial VA gain was lost over time in most patients.”
Aflibercept for neovascular age-related macular degeneration
Sarwar, S., Clearfield, E., Soliman, M. K., Sadiq, M. A., Baldwin, A. J., Hanout, M., Agarwal, A., Sepah, Y. J., Do, D. V., & Nguyen, Q. D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011346.pub2 · Cited by 142 · cited 1×
“In AMD, Phase III trials found a significant gain in best-corrected visual acuity (BCVA) after treatment that could be maintained over a course of 24 months.(1,2,11) Real-life studies, however, found only a stabilization of BCVA and the initial VA gain was lost over time in most patients.”
Bressler, S. B., Glassman, A. R., Almukhtar, T., Bressler, N. M., Ferris, F. L., Googe, J. M., Gupta, S. K., Jampol, L. M., Melia, M., & Wells, J. A. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.12.025 · Cited by 139
Cited by
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
Lanzetta, P., Korobelnik, J.-F., Heier, J. S., Leal, S., Holz, F. G., Clark, W. L., Eichenbaum, D., Iida, T., Xiaodong, S., Berliner, A. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00063-1 · Cited by 266
Metadata
- Authors
- Ehlken, C., Helms, M., Böhringer, D., Agostini, H. T., & Stahl, A.
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2017-12
- Volume
- Volume 12
- Pages
- 13-20
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- OpenAlex
- W2777721386
- Cited by
- 161
- References
- 3
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. https://app.cochat.ai/papers/10.2147/opth.s151611
- The paper
- Ehlken, C., Helms, M., Böhringer, D., Agostini, H. T., & Stahl, A. (2017). Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clinical Ophthalmology. https://doi.org/10.2147/opth.s151611
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.